Trial: 202007149

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Phase

I/II (Cancer Control)

Principal Investigator

Picus, Joel

Disease Site

Urinary Bladder

Learn more about this study at: clinicaltrials.gov